Jupiter Neurosciences (JUNS) Return on Assets (2024 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Return on Assets of 0.05% for Q4 2025, down 3.0% year-over-year from 0.05% in Q4 2024, and up 13.08% quarter-over-quarter from 0.06% in Q3 2025.
Jupiter Neurosciences (JUNS) Return on Assets (2024 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Return on Assets for 2 consecutive years, with 0.05% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Assets fell 3.0% year-over-year to 0.05%; the TTM figure through Dec 2025 stood at 0.05% (down 3.0% YoY), while the FY2025 annual figure was 0.02%, up 32.0% from the prior year.
- Return on Assets rose to 0.05% in Q4 2025 per JUNS's latest filing, from 0.06% in the prior quarter.
- Across five years, Return on Assets topped out at 0.01% in Q1 2025 and bottomed at 0.06% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 0.00% |
| 10 | Jupiter Neurosciences | 3.35 Mn | 1.83 Mn | 21,064.00 | -0.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.05% |
| Sep 30, 2025 | -0.06% |
| Jun 30, 2025 | -0.03% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.02% |